Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wuhan YZY Biopharma Co., Ltd. Class H ( (HK:2496) ) has provided an announcement.
Wuhan YZY Biopharma Co., Ltd. announced its unaudited consolidated interim results for the first half of 2025, reporting a revenue of RMB 37,187,000 and a gross profit of RMB 7,669,000. Despite a decrease in research and development expenses compared to the previous year, the company reported a loss of RMB 58,834,000, highlighting ongoing financial challenges. The results reflect the company’s continued investment in R&D, impacting its financial performance but potentially positioning it for future growth in the biopharmaceutical sector.
The most recent analyst rating on (HK:2496) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Wuhan YZY Biopharma Co., Ltd. Class H stock, see the HK:2496 Stock Forecast page.
More about Wuhan YZY Biopharma Co., Ltd. Class H
Wuhan YZY Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on research and development, with a significant emphasis on innovative therapeutics.
Average Trading Volume: 2,705
Technical Sentiment Signal: Hold
See more insights into 2496 stock on TipRanks’ Stock Analysis page.